Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (Oncogene, (2021), 40, 1, (189-202), 10.1038/s41388-020-01515-5)

Che Pei Kung, Kyle A. Cottrell, Sua Ryu, Emily R. Bramel, Raleigh D. Kladney, Emily A. Bao, Eric C. Freeman, Thwisha Sabloak, Leonard Maggi, Jason D. Weber

Research output: Contribution to journalComment/debate

Abstract

The original version of this article unfortunately contained a mistake. The following correction has therefore been made in the original: The word “orthopedic” was changed to “orthotopic” in subheading “Mammary gland orthotopic implantation” and in the first sentence of section “Mammary gland orthotopic implantation”: “The abilities of human breast cancer cell lines to form tumors in vivo were evaluated by performing mammary gland orthotopic implantation as described previously, further details can be found in the Supplementary Information [48].” The original article has been corrected.

Original languageEnglish
Pages (from-to)2147
Number of pages1
JournalOncogene
Volume40
Issue number11
DOIs
StatePublished - Mar 18 2021

Fingerprint Dive into the research topics of 'Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (Oncogene, (2021), 40, 1, (189-202), 10.1038/s41388-020-01515-5)'. Together they form a unique fingerprint.

Cite this